PFKFB3 regulates breast cancer tumorigenesis and Fulvestrant sensitivity by affecting ERα stability
Cellular Signalling · 2024
DOI: 10.1016/j.cellsig.2024.111184 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Signalling, 2024. Verfasst von Wenzhi Jia und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Phosphofructokinase-2, Estrogen Receptor alpha, Breast Neoplasms, Fulvestrant. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Estrogen receptor alpha (ERα) is expressed in approximately 70% of breast cancer cases and determines the sensitivity and effectiveness of endocrine therapy. 6-phosphofructo-2-kinase/fructose-2, 6-biphosphatase3 (PFKFB3) is a glycolytic enzyme that is highly expressed in a great many human tumors, and recent studies have shown that it plays a significant role in improving drug sensitivity. However, the role of PFKFB3 in regulating ERα expression and the underlying mechanism remains unclear. Here, we find by using immunohistochemistry (IHC) that PFKFB3 is elevated in ER-positive breast cancer and high expression of PFKFB3 resulted in a worse prognosis. In vitro and in vivo experiments verify that PFKFB3 promotes ER-positive breast cancer cell proliferation. The overexpression of PFKFB3 promotes the estrogen-independent ER-positive breast cancer growth. In an estrogen-free condition, RNA-sequencing data from MCF7 cells treated with siPFKFB3 showed enrichment of the estrogen signaling pathway, and a luciferase assay demonstrated that knockdown of PFKFB3 inhibited the ERα transcriptional activity. Mechanistically, down-regulation of PFKFB3 promotes STUB1 binding to ERα, which accelerates ERα degradation by K48-based ubiquitin linkage. Finally, growth of ER-positive breast cancer cells in vivo was more potently inhibited by fulvestrant combined with the PFKFB3 inhibitor PFK158 than for each drug alone. In conclusion, these data suggest that PFKFB3 is identified as an adverse prognosis factor for ER-positive breast cancer and plays a previously unrecognized role in the regulation of ERα stability and activity. Our results further explores an effective approach to improve fulvestrant sensitivity through the early combination with a PFKFB3 inhibitor.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Nuclear Medicine, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Institute of Clinical Nuclear Medicine, Shanghai Jiao Tong University School of Medicine, Shanghai, Chi…
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Jia, W., Wu, Q., Shen, M., Yu, X., An, S., Zhao, L., Huang, G., & Liu, J. (2024). PFKFB3 regulates breast cancer tumorigenesis and Fulvestrant sensitivity by affecting ERα stability. Cellular Signalling. https://doi.org/10.1016/j.cellsig.2024.111184
Vancouver
Jia W, Wu Q, Shen M, Yu X, An S, Zhao L, et al. PFKFB3 regulates breast cancer tumorigenesis and Fulvestrant sensitivity by affecting ERα stability. Cellular Signalling. 2024. doi:10.1016/j.cellsig.2024.111184
BibTeX
@article{Jia2024,
author = {Jia, Wenzhi and Wu, Qianyun and Shen, Mengqin and Yu, Xiaofeng and An, Shuxian and Zhao, Li and Huang, Gang and Liu, Jianjun},
title = {PFKFB3 regulates breast cancer tumorigenesis and Fulvestrant sensitivity by affecting ERα stability},
journal = {Cellular Signalling},
year = {2024},
doi = {10.1016/j.cellsig.2024.111184}
}
EUVIMED